Evidence map›Paper›PMID 34531471›Full record

ArticleScientific reports2021

A combination approach of pseudotime analysis and mathematical modeling for understanding drug-resistant mechanisms.

Shigeyuki Magi, Sewon Ki, Masao Ukai, Elisa Domínguez-Hüttinger, Atsuhiko T Naito, Yutaka Suzuki, Mariko Okada

Abstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Shigeyuki MagiLaboratory of Cell Systems, Institute for Protein Research, Osaka University, Osaka, 565-0871, Japan. shigeyuki.magi@med.toho-u.ac.jp.
Sewon KiLaboratory for Integrated Cellular Systems, RIKEN Center for Integrative Medical Sciences (IMS), Yokohama, 230-0045, Japan.
Masao UkaiGraduate School of Medical Life Science, Yokohama City University, Yokohama, 230-0045, Japan.
Elisa Domínguez-HüttingerDepartamento de Biología Molecular y Biotecnología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Ciudad Universitaria, 04510, México, México.
Atsuhiko T NaitoDepartment of Physiology, Division of Cell Physiology, Faculty of Medicine, Toho University, Tokyo, 143-8540, Japan.
Yutaka SuzukiDepartment of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Chiba, 277-8562, Japan.
Mariko OkadaLaboratory of Cell Systems, Institute for Protein Research, Osaka University, Osaka, 565-0871, Japan. mokada@protein.osaka-u.ac.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer cells acquire drug resistance through the following stages: nonresistant, pre-resistant, and resistant. Although the molecular mechanism of drug resistance is well investigated, the process of drug resistance acquisition remains largely unknown. Here we elucidate the molecular mechanisms underlying the process of drug resistance acquisition by sequential analysis of gene expression patterns in tamoxifen-treated breast cancer cells. Single-cell RNA-sequencing indicates that tamoxifen-resistant cells can be subgrouped into two, one showing altered gene expression related to metabolic regulation and another showing high expression levels of adhesion-related molecules and histone-modifying enzymes. Pseudotime analysis showed a cell transition trajectory to the two resistant subgroups that stem from a shared pre-resistant state. An ordinary differential equation model based on the trajectory fitted well with the experimental results of cell growth. Based on the established model, it was predicted and experimentally validated that inhibition of transition to both resistant subtypes would prevent the appearance of tamoxifen resistance.

Indexed as

Models, TheoreticalAntineoplastic Agents, HormonalBreast NeoplasmsCell ProliferationDrug Resistance, NeoplasmFemaleGene Expression Regulation, NeoplasticHumansMCF-7 CellsTamoxifenAntineoplastic Agents, HormonalTamoxifen

Identifiers

PMID34531471
PMCPMC8445918

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.